We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App




Greiner Bio-One Launches New Safety Blood Collection Set

By LabMedica International staff writers
Posted on 25 Jun 2018
Greiner Bio-One (Kremsmünster, Austria) has made a new addition to its range of safety products and now offers its customers an even wider selection of safety blood collection sets with the launch of the VACUETTE SAFETY Winged Set.

Approximately one-third of all occupational incidents in healthcare involve needlestick injuries. More...
Nurses are particularly at a risk of being infected by blood-borne diseases such as hepatitis B, hepatitis C and HIV. The use safety products for taking blood samples lowers the risk of needlestick injuries.

Greiner Bio One develops, manufactures, and supplies specimen collection systems, and products for pharmaceutical substance screening. The company offers pre-analytical products for collecting and processing human samples, including venous and capillary blood collection systems, urine collection systems, blood collection systems for neonates and infants, safety products, accessories, transport lines, disposals, instruments, saliva collection and quantification systems, and others.

In response to the demand for its safety products, Greiner Bio One has expanded its existing range with the launch of the new VACUETTE SAFETY Winged Set. Each of the VACUETTE SAFETY Winged Sets is equipped with a safety mechanism, which offers three different options for activating it immediately after blood collection. The safety mechanism makes a clearly audible click to confirm that the needle is safely and irreversibly locked in the safety shield. In order to provide users with more choice, the safety blood collection set is available both with and without a pre-assembled blood culture holder. Additionally, its transparent product design provides optimal blood flow visibility.


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.